Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Two out of the three major indices are trading lower today with the Dow Jones Industrial Average ( ^DJI) trading down 57 points (-0.3%) at 16,357 as of Wednesday, Jan. 22, 2014, 11:55 AM ET. The NYSE advances/declines ratio sits at 1,698 issues advancing vs. 1,213 declining with 185 unchanged.

The Health Services industry currently sits up 0.2% versus the S&P 500, which is down 0.1%. Top gainers within the industry include DaVita HealthCare Partners ( DVA), up 0.9%, and Agilent Technologies ( A), up 0.5%. On the negative front, top decliners within the industry include Boston Scientific ( BSX), down 1.0%, Medtronic ( MDT), down 0.8% and WellPoint ( WLP), down 0.6%.

TheStreet would like to highlight 4 stocks pushing the industry higher today:

4. Smith & Nephew ( SNN) is one of the companies pushing the Health Services industry higher today. As of noon trading, Smith & Nephew is up $0.60 (0.8%) to $73.79 on light volume. Thus far, 20,532 shares of Smith & Nephew exchanged hands as compared to its average daily volume of 75,600 shares. The stock has ranged in price between $73.48-$73.80 after having opened the day at $73.79 as compared to the previous trading day's close of $73.19.

Smith & Nephew plc develops, manufactures, markets, and sells medical devices in the advanced surgical devices and advanced wound management sectors worldwide. Smith & Nephew has a market cap of $12.9 billion and is part of the health care sector. The company has a P/E ratio of 19.2, above the S&P 500 P/E ratio of 17.7. Shares are up 2.0% year-to-date as of the close of trading on Tuesday. Currently there are 3 analysts who rate Smith & Nephew a buy, no analysts rate it a sell, and 4 rate it a hold.

TheStreet Ratings rates Smith & Nephew as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, reasonable valuation levels, expanding profit margins and solid stock price performance. We feel these strengths outweigh the fact that the company has had somewhat disappointing return on equity. Get the full Smith & Nephew Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

3. As of noon trading, Parexel International Corporation ( PRXL) is up $1.65 (3.6%) to $47.65 on average volume. Thus far, 376,213 shares of Parexel International Corporation exchanged hands as compared to its average daily volume of 716,600 shares. The stock has ranged in price between $46.54-$47.77 after having opened the day at $47.06 as compared to the previous trading day's close of $46.00.

PAREXEL International Corporation, a biopharmaceutical services company, provides clinical research, medical communications, consulting, commercialization, and advanced technology products and services to the pharmaceutical, biotechnology, and medical device industries worldwide. Parexel International Corporation has a market cap of $2.6 billion and is part of the health care sector. The company has a P/E ratio of 25.4, above the S&P 500 P/E ratio of 17.7. Shares are up 1.8% year-to-date as of the close of trading on Tuesday. Currently there are 4 analysts who rate Parexel International Corporation a buy, 1 analyst rates it a sell, and 5 rate it a hold.

TheStreet Ratings rates Parexel International Corporation as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, solid stock price performance, impressive record of earnings per share growth, compelling growth in net income and notable return on equity. We feel these strengths outweigh the fact that the company shows weak operating cash flow. Get the full Parexel International Corporation Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

2. As of noon trading, Mindray Medical International Limited ADR r ( MR) is up $0.93 (2.5%) to $37.93 on light volume. Thus far, 356,951 shares of Mindray Medical International Limited ADR r exchanged hands as compared to its average daily volume of 1.1 million shares. The stock has ranged in price between $37.00-$38.09 after having opened the day at $37.47 as compared to the previous trading day's close of $37.00.

Mindray Medical International Limited, through its subsidiary, Shenzhen Mindray, develops, manufactures, and markets medical devices worldwide. It operates in three segments: Patient Monitoring and Life Support Products, In-Vitro Diagnostic Products, and Medical Imaging Systems. Mindray Medical International Limited ADR r has a market cap of $4.6 billion and is part of the health care sector. The company has a P/E ratio of 21.2, above the S&P 500 P/E ratio of 17.7. Shares are up 1.8% year-to-date as of the close of trading on Tuesday. Currently there are 5 analysts who rate Mindray Medical International Limited ADR r a buy, 1 analyst rates it a sell, and 2 rate it a hold.

TheStreet Ratings rates Mindray Medical International Limited ADR r as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, reasonable valuation levels, good cash flow from operations and expanding profit margins. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results. Get the full Mindray Medical International Limited ADR r Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

1. As of noon trading, Stryker Corporation ( SYK) is up $0.50 (0.6%) to $79.09 on average volume. Thus far, 648,963 shares of Stryker Corporation exchanged hands as compared to its average daily volume of 1.3 million shares. The stock has ranged in price between $78.49-$79.24 after having opened the day at $78.59 as compared to the previous trading day's close of $78.59.

Stryker Corporation, a medical technology company, provides reconstructive, medical and surgical, and neurotechnology and spine products for doctors, hospitals, and other healthcare facilities. Stryker Corporation has a market cap of $29.6 billion and is part of the health care sector. The company has a P/E ratio of 33.6, above the S&P 500 P/E ratio of 17.7. Shares are up 4.6% year-to-date as of the close of trading on Tuesday. Currently there are 13 analysts who rate Stryker Corporation a buy, 1 analyst rates it a sell, and 10 rate it a hold.

TheStreet Ratings rates Stryker Corporation as a hold. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures and good cash flow from operations. However, as a counter to these strengths, we also find weaknesses including deteriorating net income, disappointing return on equity and feeble growth in the company's earnings per share. Get the full Stryker Corporation Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

If you are interested in one of these 4 stocks, ETFs may be of interest. Investors who are bullish on the health services industry could consider Health Care Select Sector SPDR ( XLV) while those bearish on the health services industry could consider ProShares Ultra Short Health Care ( RXD).

null